LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,074 shares of the medical instruments supplier’s stock after selling 677 shares during the period. Oak Ridge Investments LLC’s holdings in LeMaitre Vascular were worth $1,942,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LMAT. Acadian Asset Management LLC purchased a new stake in LeMaitre Vascular during the 2nd quarter worth about $104,000. Envestnet Asset Management Inc. lifted its stake in shares of LeMaitre Vascular by 0.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 215,841 shares of the medical instruments supplier’s stock worth $17,759,000 after purchasing an additional 1,520 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of LeMaitre Vascular by 3.1% during the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the medical instruments supplier’s stock worth $11,527,000 after purchasing an additional 4,164 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of LeMaitre Vascular in the second quarter valued at $82,000. Finally, Sei Investments Co. increased its stake in LeMaitre Vascular by 2.0% in the second quarter. Sei Investments Co. now owns 59,211 shares of the medical instruments supplier’s stock valued at $4,872,000 after purchasing an additional 1,140 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 0.8 %

Shares of LMAT stock opened at $99.06 on Friday. The company has a market cap of $2.23 billion, a PE ratio of 54.13, a P/E/G ratio of 2.07 and a beta of 0.96. The company’s fifty day simple moving average is $98.48 and its 200-day simple moving average is $91.87. LeMaitre Vascular, Inc. has a 52 week low of $56.04 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same period last year, the company posted $0.33 earnings per share. The firm’s revenue was up 15.6% compared to the same quarter last year. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.65%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

Analysts Set New Price Targets

LMAT has been the topic of a number of research analyst reports. Cantor Fitzgerald began coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Barrington Research boosted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Oppenheimer restated an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

Insider Activity

In other news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.